Visualize how your peptide clears from the body — half-life, steady state, and accumulation for every injection schedule.
Half-Life
~3 h
Time for 50 % to be eliminated
Steady State
~11 h
≈ 4.3 half-lives
Accumulation
×1.04
Cmax at steady state ÷ Cmax first dose
Gone After
~18 h
after last dose
| Hour | % of peak |
|---|---|
| 0 | 100 |
| 8.4 | 9.7 |
| 16.1 | 33.2 |
| 24 | 103.7 |
| 32.2 | 10.7 |
| 39.9 | 35.2 |
| 48 | 103.7 |
| 56 | 11.3 |
| 63.7 | 37.2 |
| 72 | 103.7 |
| 79.8 | 11.9 |
| 88.2 | 32.4 |
| 96.6 | 3.2 |
| 105 | 0.3 |
| 113.4 | 0 |
| 121.8 | 0 |
| 130.2 | 0 |
| 138.6 | 0 |
| 147 | 0 |
| 155.4 | 0 |
| 163.8 | 0 |
Source: Heffernan et al., GH fragment PK. Research tool. Uses a simplified first-order elimination model and normalizes concentration to % of peak. Not a medical or dosing recommendation. HGH Fragment 176-191: ~2.5 hours.
HGH Fragment 176-191 has a reported half-life of about 2.5 hours. Under a once- or twice-daily dosing schedule, steady state is reached at roughly 4.3 half-lives, about 11 hours, and accumulation is essentially negligible: each dose clears almost fully before the next.
The blue line plots concentration as a percentage of the first-dose peak. The dashed reference line marks the steady-state peak. After the last dose, concentration drops below 1 % of the peak after about 17.5 hours, seven half-lives.
HGH Fragment 176-191 is the C-terminal fragment (amino acids 176-191) of human growth hormone, studied for its lipolytic and metabolic effects without the growth-promoting activity of full-length GH. Typical daily doses range from 0.1 to 0.5 mg. The short half-life means each dose is pharmacokinetically independent, and twice-daily protocols are used to extend the exposure window.